Literature DB >> 10192458

Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97.

T T Yee1, K J Pasi, P A Lilley, C A Lee.   

Abstract

A retrospective study of the natural history of factor VIII inhibitors in haemophilia A patients experienced in a single comprehensive haemophilia centre over three decades is reported. 431 haemophilia A patients of all severities have been followed-up for a total of 5626 patient-years. The frequency of inhibitors was 10% in the severe haemophilia A patients and 37% occurred in children <10 years. The majority of the patients received several products before developing the inhibitors. 59% of patients had <50 exposure days and 48% were high responders (>5 BU). An 8-year (1987-95) inhibitor-free period was seen during which all previously untreated patients were treated with an intermediate-purity factor VIII concentrate. A moderate haemophiliac with a missense mutation that has not been described in association with inhibitor is reported. Six HIV-positive patients preserved their antibody response to factor VIII even at the advanced stage of their disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10192458     DOI: 10.1046/j.1365-2141.1999.01268.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

2.  Inhibitor development in two patients with mild haemophilia A - spontaneous disappearance and no recurrence of the inhibitor after re-challenge.

Authors:  Sylvia Reitter-Pfoertner; Birgit Horvath; Klaus Lechner; Raute Sunder-Plassmann; Christine Mannhalter; Ingrid Pabinger
Journal:  Wien Klin Wochenschr       Date:  2012-01-18       Impact factor: 1.704

Review 3.  Spontaneous multilevel airway haemorrhage in acquired haemophilia A.

Authors:  Anna See; Siti Radhziah Sudirman; Xin Yong Huang
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-30       Impact factor: 2.503

Review 4.  Immune response to FVIII in hemophilia A: an overview of risk factors.

Authors:  Kanjaksha Ghosh; Shrimati Shetty
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

5.  Acquired haemophilia A as a blood transfusion emergency.

Authors:  Giuseppe Tagariello; Roberto Sartori; Paolo Radossi; Renzo Risato; Giovanni Roveroni; Cristina Tassinari; Annachiara Giuffrida; Giorgio Gandini; Massimo Franchini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 6.  Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.

Authors:  Davide Matino; Michael Makris; Kerry Dwan; Roberto D'Amico; Alfonso Iorio
Journal:  Cochrane Database Syst Rev       Date:  2015-12-16

Review 7.  Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders.

Authors:  Pär I Johansson; Sisse R Ostrowski
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

8.  Life-threatening hemorrhage from acquired hemophilia A as a presenting manifestation of prostate cancer.

Authors:  Chirag Sheth; Amandeep Gill; Sumeet Sekhon
Journal:  J Community Hosp Intern Med Perspect       Date:  2016-09-07

9.  An Acquired Factor VIII Inhibitor in a Patient with HIV and HCV: A Case Presentation and Literature Review.

Authors:  S B Zeichner; A Harris; G Turner; M Francavilla; J Lutzky
Journal:  Case Rep Hematol       Date:  2013-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.